Literature DB >> 34716463

Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing.

Divya Ravirala1, Guangsheng Pei2, Zhongming Zhao2,3, Xiaoliu Zhang4,5.   

Abstract

An important mechanism of oncolytic virotherapy in ameliorating cancer immunotherapy is by inducing significant changes in the immune landscape in the tumor microenvironment (TME). Despite this notion and the potential therapeutic implications, a comprehensive analysis of the immune changes in carcinomas induced by virotherapy has not yet been elucidated. We conducted single-cell RNA sequencing analysis on carcinomas treated with an HSV-2-based oncolytic virus to characterize the immunogenic changes in the TME. We specifically analyzed and compared the immune cell composition between viral treated and untreated tumors. We also applied CellChat to analyze the complex interactions among the infiltrated immune cells. Our data revealed significant infiltration of B cells in addition to other important immune cells, including CD4+, CD8+, and NK cells following virotherapy. Further analysis identified distinct subset compositions of the infiltrated immune cells and their activation status upon virotherapy. The intensive interactions among the infiltrated immune cells as revealed by CellChat analysis may further shape the immune landscape in favor of generating antitumor immunity. Our findings will facilitate the design of new strategies in incorporating immunotherapy into virotherapy for clinical translation. Moreover, the significant infiltration of B cells makes it suitable for combining virotherapy with immune checkpoint inhibitors.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Immune landscape; Oncolytic herpes simplex virus; Single-cell RNA sequencing; Tumor microenvironment; Virotherapy

Mesh:

Year:  2021        PMID: 34716463     DOI: 10.1007/s00262-021-03084-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  38 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.

Authors:  Hong Jae Chon; Won Suk Lee; Hannah Yang; So Jung Kong; Na Keum Lee; Eun Sang Moon; Jiwon Choi; Eun Chun Han; Joo Hoon Kim; Joong Bae Ahn; Joo Hang Kim; Chan Kim
Journal:  Clin Cancer Res       Date:  2018-12-11       Impact factor: 12.531

Review 3.  Oncolytic Virotherapy and the Tumor Microenvironment.

Authors:  Sara E Berkey; Steve H Thorne; David L Bartlett
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 4.  Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.

Authors:  Gerald P Linette; Beatriz M Carreno
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 5.  Cytokines in oncolytic virotherapy.

Authors:  Jonathan G Pol; Samuel T Workenhe; Prathyusha Konda; Shashi Gujar; Guido Kroemer
Journal:  Cytokine Growth Factor Rev       Date:  2020-11-02       Impact factor: 7.638

6.  Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.

Authors:  Hongtao Li; Aurelie Dutuor; Xinping Fu; Xiaoliu Zhang
Journal:  J Gene Med       Date:  2007-03       Impact factor: 4.565

7.  The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.

Authors:  Anton Uryvaev; Maria Passhak; Dov Hershkovits; Edmond Sabo; Gil Bar-Sela
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

Review 8.  Talimogene laherparepvec: First in class oncolytic virotherapy.

Authors:  Robert M Conry; Brian Westbrook; Svetlana McKee; Timothy Graham Norwood
Journal:  Hum Vaccin Immunother       Date:  2018-02-22       Impact factor: 3.452

Review 9.  Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.

Authors:  Taylor M Pearl; James M Markert; Kevin A Cassady; Mohammed G Ghonime
Journal:  Mol Ther Oncolytics       Date:  2019-03-20       Impact factor: 7.200

10.  Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer.

Authors:  Jing Ma; Mohanraj Ramachandran; Chuan Jin; Clara Quijano-Rubio; Miika Martikainen; Di Yu; Magnus Essand
Journal:  Cell Death Dis       Date:  2020-01-22       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.